SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is generating significant market buzz ahead of its quarterly earnings release as investors weigh the company's aggressive pivot toward the data center CPU market against its high valuation. The community remains sharply divided, with bulls pointing to robust demand for AI-driven compute as a long-term catalyst, while bears argue that supply chain constraints and the recent vertical price rally suggest a bubble-like environment susceptible to a post-earnings selloff.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors weigh strong Q1 earnings results, including improved free cash flow and user growth, against cautious guidance and the termination of a partnership. The community is actively debating the effectiveness of leadership and debating the potential for a long-term turnaround driven by cost-cutting initiatives and future hardware developments.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is gaining market attention as shareholders of Warner Bros. Discovery prepare for an upcoming pivotal vote on their proposed $110 billion merger. Community sentiment remains split, with some traders optimistic about the consolidation's long-term synergy potential while others voice frustration over price volatility and the broader implications of the deal's structure.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN Limited is trending as the community closely monitors its recent $625 million acquisition of Mirantis and anticipates upcoming earnings, fueling debates over the company's shift toward a full-stack AI cloud model. Investors are actively discussing the potential for major hyperscaler contract announcements and whether this move effectively bridges the gap in their AI software capabilities.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing strong momentum as investors weigh a potential buyout against the company's scaling revenue and upcoming clinical catalysts. The community is actively discussing the strong adoption of BRIUMVI and anticipation surrounding the subcutaneous formulation trial results, which many view as a critical inflection point for the stock.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is trending as investors react to a significant milestone where the company surpassed 200,000 policies through its partnership with Carvana, triggering the exercisability of warrants. Community discussion remains heavily polarized between bulls betting on rapid partnership-led growth and share buybacks, and bears highlighting persistent management insider selling, executive compensation concerns, and questions regarding the long-term sustainability of the current growth model.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending following an earnings beat that exceeded profit expectations and reaffirmed revenue guidance, sparking significant buying interest from the community. Investors are closely tracking the company's path to profitability and margin expansion, with many debating whether the current momentum marks the start of a sustained reversal.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is currently in focus as investors analyze the stock's sharp volatility following a contentious short-seller report and the company's subsequent rebuttal. The community is actively debating the stock's fundamental valuation, with many traders weighing the impact of share repurchases, recent regulatory developments, and potential earnings performance against the backdrop of competitive headwinds.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing increased bullish sentiment and volume, driven by excitement over its QNX software's expanding role in robotics and Physical AI partnerships. The community is actively tracking the stock's pivot toward software-driven growth and is closely monitoring potential institutional accumulation.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is seeing significant volatility following the release of preclinical data showing complete tumor clearance in ovarian cancer models, with the community polarized between optimism over the clinical potential and skepticism regarding historical share structure changes like reverse splits. Traders are heavily focused on the stock's low float and high short interest, fueling intense debate over whether the recent price action represents a legitimate breakthrough or a setup for further dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanguard Announces Share Splits for Five Equity Index ETFs

Vanguard Announces Share Splits for Five Equity Index ETFs Vanguard Announces Share Splits for Five Equity Index ETFs PR Newswire VALLEY FORGE, Pa., March 24, 2026 VALLEY FORGE, Pa., March 24, 2026...

Should Vanguard S&P 500 Growth Index Fund ETF Shares (VOOG) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Patients treated with povetacicept also demonstrated a 77.4% reduction from baseline in serum galactose deficient IgA1, a critical, disease-specific biomarker for IgA nephropathy, the company added.</li><li>Vertex now expects to complete necessary submissions seeking approval for povetacicept in IgA Nephropathy by March.</li><li>The company has a priority review voucher which would allow it to reduce the review time from ten months to six, it added.</li></ul><p><br>Shares of Vertex Pharmaceuticals Incorporated (VRTX) rose as much as 7% after hours on Monday after the company announced positive 36-week data from its ongoing late-stage trial evaluating povetacicept in immunoglobulin A nephropathy.</p><p>IgA nephropathy or Berger’s disease is an autoimmune kidney disease occurring when immunoglobulin A (IgA) antibody clumps deposit in the kidney’s glomeruli, causing inflammation and damage.</p><h2 class="st-heading-2">Trial Takeaways</h2><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-week-36-interim-analysis-results">said</a> that patients treated with povetacicept on top of standard of care achieved a 52% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal. The reduction was consistent across subgroups, the company said. &nbsp;</p><p>Patients treated with povetacicept also demonstrated a 77.4% reduction from baseline in serum galactose deficient IgA1, a critical, disease-specific biomarker for IgA nephropathy, the company added.</p><p>Povetacicept was generally safe and well tolerated with a majority of adverse events (AEs) being mild to moderate. There were no serious adverse events or deaths, and no discontinuations due to infections, the company added.</p><h2 class="st-heading-2">Plans Ahead</h2><p>Vertex now expects to complete necessary submissions seeking approval for povetacicept in IgA Nephropathy by March. The company has a priority review voucher which would allow it to reduce the review time from ten months to six, it added.</p><p>If approved, the company expects to launch povetacicept in a low volume subcutaneous auto-injector delivered once every four weeks via at-home administration.</p><p>Other companies with FDA-approved drugs for IgA Nephropathy include Travere Therapeutics and Novartis.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around VRTX shares stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.</p><p><a href="https://stocktwits.com/symbol/VRTX">VRTX stock</a> has declined 8% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/voyg-shares-decline-on-double-q4-miss-despite-record-2025-backlog/cZdVUXLRIeI">VOYG Shares Decline On Double Q4 Miss Despite Record 2025 Backlog</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, Vertex Pharmaceuticals' logo is displayed on a smartphone screen in front of a stock chart. (Photo illustration by Cheng Xin/Getty Images)

VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease

The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal.

Equity

Should Vanguard S&P 500 Growth ETF (VOOG) Be on Your Investing Radar?

Growth ETF (VOOG) Hits New 52-Week High

VOOG hits a 52-week high amid tech-driven momentum and optimism over Fed rate cuts, hinting at more upside ahead.

Less-Than-Expected Inflation in July: Growth ETFs to Gain?

CPI rose less than expected, boosting hopes for Fed rate cuts and sparking interest in top growth-focused ETFs like VUG and RPG.



Three Rate Cuts Expected in 2025? ETFs in Focus 

Fed officials signal possible rate cuts this year, boosting the appeal of growth-focused ETFs amid slowing labor market trends. Tap ETFs like VUG, RPG and VOOG.

Fed to Cut Rates Ahead? Growth ETFs to Play 

Weak hiring and rising jobless rates have San Francisco Fed President Mary Daly eyeing Fed rate cuts. If the Fed cuts rates soon, growth ETFs like RPG and IVW could benefit.

Growth ETFs Set New Records, Brush Off Tariff Headwinds

Growth ETFs like MGK, VUG, IWY, IUSG, and SPYG and others hit fresh highs as investors shrug off tariff threats and chase AI-fueled momentum.


Vanguard Admiral Funds - Vanguard S&P 500 Growth ETF

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

VOOG
Vanguard S&P 500 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest VOOG News

VOOGVanguard S&P 500 Growth ETF